GPC3 and hepatocellular carcinoma: To allow more patients to benefit from codrituzumab treatment, we recommend that future studies to be conducted in a population of GPC3 IHC 1+, 2+, 3+ and CD16 MESF above the 25th percentile, which comprises approximately 63% of total HCC population.